Quick Answer
VIEMED HEALTHCARE, INC. reported Research And Development Expense of $3.02 million for the year ending 2025.
- VIEMED HEALTHCARE, INC. showed a decrease of -1.7% in Research And Development Expense from 2024 to 2025.
- This data is from VIEMED HEALTHCARE, INC.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $0.00 | Q2 2018: $0.00 | Q3 2018: $0.00 | Q4 2018: $0.00 | Q1 2019: $234.0 thousand | Q2 2019: $203.0 thousand | Q3 2019: $208.0 thousand | Q1 2020: $174.0 thousand | Q2 2020: $271.0 thousand | Q3 2020: $243.0 thousand | Q1 2021: $339.0 thousand | Q2 2021: $583.0 thousand | Q3 2021: $576.0 thousand | Q1 2022: $632.0 thousand | Q2 2022: $672.0 thousand | Q3 2022: $670.0 thousand | Q1 2023: $780.0 thousand | Q2 2023: $758.0 thousand | Q3 2023: $593.0 thousand | Q1 2024: $750.0 thousand | Q2 2024: $758.0 thousand | Q3 2024: $757.0 thousand | Q1 2025: $797.0 thousand | Q2 2025: $847.0 thousand | Q3 2025: $775.0 thousand.
- Historical annual values: Fiscal year 2025: $3.02 million | Fiscal year 2024: $3.07 million | Fiscal year 2023: $2.78 million | Fiscal year 2022: $2.70 million | Fiscal year 2021: $2.11 million | Fiscal year 2020: $1.08 million | Fiscal year 2019: $848.0 thousand | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: